The genome and the consumer

Research output: Contribution to journalReview articlepeer-review

Abstract

Consumergenetics has developed so fast that it became possible for consumers to obtain genome risk information based on single nucleotide polymorphisms data of over 250 diseases/conditions for just 99 USD. In November 2013, the American Food and Drug Administration (FDA) ordered the company 23andMe to stop returning health results because they found a lack of scientific evidence of the reposted disease risks. The ethical dilemmas associated with this are reviewed, and the recommendations are described in genome testing. Ethical dilemmas in relation direct-to-consumer testing are discussed.

Original languageEnglish
JournalUgeskrift for laeger
Volume176
Issue number46
Publication statusPublished - 10 Nov 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'The genome and the consumer'. Together they form a unique fingerprint.

Cite this